Acquired ESR1 mutations are a major mechanism of resistance to aromatase inhibitors (AIs). We developed ultra highsensitivity multiplex digital polymerase chain reaction assays for ESR1 mutations in circulating tumor DNA (ctDNA) and investigated the clinical relevance and origin of ESR1 mutations in 171 women with advanced breast cancer. ESR1 mutation status in ctDNA showed high concordance with contemporaneous tumor biopsies and was accurately assessed in samples shipped at room temperature in preservative tubes. ESR1 mutations were found exclusively in estrogen receptor-positive breast cancer patients previously exposed to AI. Patients with ESR1 mutations had a substantially shorter progression-free survival on subsequent AI-based therapy [hazard ratio, 3.1; 95% confidence interval (CI), 1.9 to 23.1; P = 0.0041]. ESR1 mutation prevalence differed markedly between patients who were first exposed to AI during the adjuvant and metastatic settings [5.8% (3 of 52) versus 36.4% (16 of 44), respectively; P = 0.0002]. In an independent cohort, ESR1 mutations were identified in 0% (0 of 32; 95% CI, 0 to 10.9) tumor biopsies taken after progression on adjuvant AI. In a patient with serial sampling, ESR1 mutation was selected during metastatic AI therapy to become the dominant clone in the cancer. ESR1 mutations can be robustly identified with ctDNA analysis and predict for resistance to subsequent AI therapy. ESR1 mutations are rarely acquired during adjuvant AI but are commonly selected by therapy for metastatic disease, providing evidence that mechanisms of resistance to targeted therapy may be substantially different between the treatment of micrometastatic and overt metastatic cancer.
INTRODUCTION
Cancer evolution and progression are driven by a sequence of somatic genetic and nongenetic alterations resulting in more favorable tumor cell growth and survival. Cancer genetic evolution is subject to intrinsic influences such as the tumor microenvironment, as well as extrinsic pressures such as drug therapy (1). The clinical pattern of "acquired" resistance may, in many circumstances, represent outgrowth of resistant clones, which may have originally been present in the cancer at low frequency as a result of intratumoral genetic heterogeneity (2, 3), but grow out under the selective pressure of targeted therapy (1). For example, HER2 amplification is acquired in about 2 to 5% of metastatic breast cancers that were originally HER2-nonamplified (4) . MET amplification may be selected out as a mechanism of resistance to epidermal growth factor receptor (EGFR) inhibitor therapy in non-small cell lung cancer (2), with the underlying biology behind selection of genetic events, at least in part, reflecting intratumoral heterogeneity and clonal selection.
With the potential of tumor genetics to evolve through treatment, repeat sampling of a tumor would be required to optimally guide therapy because the mechanism of resistance may not be evident in analyses of the tumor before treatment. Yet, serial biopsies of recurrent, metastatic cancer would be invasive, risky, and unacceptable to many patients (5) . Tumor-derived DNA is found in the plasma of patients with recurrent cancer, and high-depth analysis of circulating tumor DNA (ctDNA) presents a noninvasive way of analyzing tumor genetics and "acquisition" of selected genetic events throughout the course of treatment (6, 7) .
About 75% of breast cancers express the estrogen receptor (ER), with hormone therapies being the mainstay of treatment for this group of patients. Hormone resistance is frequent in the treatment of early breast cancer and inevitable in metastatic breast cancer. Recently, mutations in the ER gene (ESR1) have been described in advanced breast cancers that had been exposed to previous therapy with aromatase inhibitors (AIs) (8) (9) (10) (11) , drugs that suppress estrogen in postmenopausal women through inhibition of androgen aromatization. ESR1 mutations are only rarely detectable in primary breast cancer and are only found at appreciable frequency after the development of hormone resistance (11, 12) . Most of the ESR1 mutations occur in a hotspot region within the ligand-binding domain (LBD) of ER, altering amino acid 536, 537, or 538 in helix 12 (p.Leu536Arg, p.Tyr537Ser, p.Tyr537Asn, p.Tyr537Cys, and p.Asp538Gly) (8) (9) (10) (11) . Functional studies of these LBD ESR1 mutations demonstrated that they constitutively activate the ER in a ligand-independent fashion (9) . Hence, cancers with these ESR1 mutations would be predicted to be resistant to AIs and ovarian suppression in premenopausal women because these therapies work by depriving ligand. In contrast, in vitro and in vivo, LBD ESR1 mutations retain limited sensitivity to tamoxifen and fulvestrant (a selective ER modulator and a selective ER down-regulator, respectively) (8-11).
Previous studies of ESR1 mutations have been limited to patients with metastatic tumor biopsies and two small studies that have used plasma digital polymerase chain reaction (PCR) (13) and plasma amplicon sequencing (14) to detect ESR1 mutations in plasma of patients with metastatic breast cancer. Here, we used ctDNA analysis to study a large, unbiased series of consecutive patients with advanced breast cancer to determine whether these mutations can be detected noninvasively and to examine the potential clinical importance and origin of ESR1 mutations.
RESULTS
ESR1 mutations are detected in ctDNA of women with ER-positive breast cancer To investigate whether ESR1 mutations could be identified in the ctDNA, we recruited a cohort of 171 women with advanced breast cancer (table S1), all of whom had plasma samples taken at the time of disease progression, because ctDNA can become undetectable in patients responding to therapy. We developed ultrahighsensitivity multiplex digital PCR assays for ESR1 LBD mutations and used these to assess for ESR1 mutations in plasma ( Fig. 1A and table S2 ). To validate ctDNA assessment of ESR1 mutations, a subset of 31 women had a tumor biopsy contemporaneous to the plasma sample, and there was 97% agreement between tumor DNA and ctDNA analysis [ Fig. 1B ; k = 0.84; 95% confidence interval (CI), 0.53 to 1.00], with 75% sensitivity and 100% specificity for ctDNA analysis compared to tumor DNA. The single patient with an ESR1 mutation detected in tumor, but not in plasma, had a PIK3CA mutation in tumor that was also not detectable in plasma by digital PCR, suggesting that discordance reflected very low levels of ctDNA release. To assess technical reproducibility and the potential to mail samples in cell-free DNA preservative tubes, we separately collected blood samples into EDTA tubes and into DNA preservative Streck tubes. EDTA tubes were processed within 2 hours, whereas preservative tubes were mailed and processed 48 to 72 hours after venesection. There was 100% agreement between repeat plasma samples processed entirely separately, taken from the same patient at the same blood draw ( Fig. 1C ; k = 1.00; 95% CI, not estimable), with a high correlation of ESR1 mutation abundance (Fig. 1D) , providing evidence of both extremely high technical reproducibility and the ability to mail unprocessed samples in preservative tubes. In a dilution experiment, we showed that the digital PCR assays are able to detect as few as three copies of the mutant allele in an excess of wild-type DNA ( fig. S1A ).
ESR1 mutations were detected in the plasma of 10.5% (18 of 171; 95% CI, 6 to 16) of patients with advanced breast cancer, exclusively in patients with ER-positive breast cancer (ER-positive 14% versus ER-negative 0%; P = 0.0093, c 2 test; Fig. 2A ). All patients with ESR1 mutations detected had previous AI exposure, with a median duration of previous exposure of 23 months (range, 5.9 to 141.4) ( Table 1 ). None (0 of 22; 95% CI, 0 to 15) of the patients with previous tamoxifen without AI exposure had detectable ESR1 mutations. ESR1 mutation ctDNA abundance was highly correlated between multiplex and uniplex mutation assays ( fig. S1B) , with a distribution of mutations that was highly similar to previously published data ( Fig. 2B ) (8) (9) (10) (11) . ESR1 mutations were shown to be overtly polyclonal in 21% of ESR1 mutant patients and apparently monoclonal in the remaining 79% of patients (Fig. 2B) .
Detection of ESR1 mutations predicts for relative resistance to subsequent AI-based therapy We investigated sensitivity to hormonal therapy after ctDNA assessment. Patients with ESR1 mutation(s) detected in plasma had a substantially shorter progression-free survival (PFS) on subsequent AI-based therapy, whether given as therapy after disease progression [ fig. S2 ; hazard ratio (HR), 3.7; 95% CI, 1.9 to 76.9; P = 0.008, log-rank test] or including the duration of AI given as maintenance therapy after response to previous chemotherapy ( Fig. 2C ; HR, 3.1; 95% CI, 1.9 to 23.1; P = 0.0041, log-rank test). There were not enough patients who had exposure to the ER degrader fulvestrant after ctDNA assessment to assess the activity of fulvestrant in this population.
ESR1 mutations are predominantly acquired during the treatment of metastatic disease To investigate the factors that associated with detection of ESR1 mutations in ctDNA, we looked for differences in clinical and pathological factors between ER-positive cancers that were ESR1 wild type and mutant in ctDNA (Table 1) . There was no difference in grade, HER2 status, previous chemotherapy exposure, cumulative duration of previous AI therapy, or sites of metastasis. Although all patients with detectable ESR1 mutation had previous AI exposure, patients with detectable ESR1 mutations had less frequent AI exposure in the adjuvant setting (ESR1 mutant 16% versus ESR1 wild type 45%, P = 0.0216) and more frequent AI exposure in the metastatic setting (ESR1 mutant 95% versus ESR1 wild type 36%, P < 0.0001, Table 1 ). Within the subset of patients who had AI exposure only in the metastatic setting, there was no difference in cumulative duration of previous AI exposure (23.3 months ESR1 wild type versus 23.0 months ESR1 mutant; P = 0.82, Mann-Whitney U test), number of courses of previous endocrine therapy (median, 2.0 versus 1.5; P = 0.39), or duration of first AI exposure (13.2 versus 18.1 months, respectively; P = 0.47).
We further investigated whether the timing of previous AI exposure influenced the prevalence of ESR1 mutations. Strikingly, patients who had received previous AI in the adjuvant setting for the treatment of micrometastatic disease, whether followed by further therapy in the metastatic setting, had a substantially lower prevalence of ESR1 mutation(s) compared to patients who first received previous AI only for the treatment of metastatic breast cancer (5.8% versus 36.4%; Fig.  3A ; P = 0.0002, c 2 test). The subset of patients who had ctDNA samples taken at the time of recurrence on adjuvant AI also had a low rate of ESR1 mutation in ctDNA (4.8% 1 of 21), suggesting that the difference did not reflect loss of ESR1 mutation due to time between exposure to AI and taking of plasma sample for ctDNA analysis. A further confounding factor could be that plasma samples contained no ctDNA in patients exposed to AI in the adjuvant setting. To address this, we assessed the prevalence of hotspot PIK3CA mutations in plasma DNA and found similar rates of PIK3CA mutation across all groups (Fig. 3B) , suggesting that differences in ctDNA abundance did not explain the observation.
We assessed the rate of ESR1 mutations only in patients with known detectable ctDNA by assessing the rate of ESR1 mutation only in samples with another mutation detected in plasma DNA. To extend the power of this analysis beyond PIK3CA mutations identified with digital PCR, we sequenced plasma samples from 76 patients with massive parallel sequencing (MPS) using a custom Ion Torrent amplicon sequencing panel (table S3) , calling mutations with an allele frequency of >3%. Mutations with an allele frequency of 3 to 10% were additionally confirmed by digital PCR. We sequenced plasma from seven patients with ESR1 mutations identified by digital PCR and found the corresponding mutation in four (57%) of these patients, reflecting the higher sensitivity of digital PCR for low allele frequencies. Of the 69 patients without an ESR1 LBD mutation by digital PCR, none had an ESR1 LBD mutation by MPS (P < 0.0001, c 2 test). Using MPS, we identified an additional mutation (other than PIK3CA) in 13 patients. We next assessed the rate of ESR1 mutations only in the 49 patients who had experimental evidence of ctDNA being present, by either PIK3CA digital PCR or plasma DNA MPS. ESR1 mutations were found in 7% (1 of 15) of patients exposed to AI in the adjuvant setting only, in 14% (2 of 14) of patients with exposure in both adjuvant and metastatic settings, and in 42% (5 of 12) of patients with AI exposure only in the metastatic setting (Fig. 4A) . Our data suggest that ESR1 mutations were present at a higher rate in patients exposed to AI in the metastatic setting and only rarely occur in patients exposed to AI in the adjuvant setting.
To confirm these observations, we examined three independent cohorts. The first independent cohort was from 49 patients with tumor biopsies taken at the time of recurrence or at progression on AI. We identified no mutations in patients exposed to AI in the adjuvant setting (0 of 32; 95% CI, 0 to 10.9; Fig. 4B ), confirming the low incidence of ESR1 mutations in patients treated in the adjuvant setting. Conversely, mutations were identified in 12% (2 of 17) of patients exposed to AI in the metastatic setting. For the second cohort, we collected plasma samples from an additional independent set of 28 patients with metastatic breast cancer, 18 of whom had previous AI treatment. In those with previous AI therapy in the adjuvant setting, we identified ESR1 mutations in 0% (0 of 7) of patients, whereas in those who had received previous AI only in the metastatic setting, we identified ESR1 mutations in 36% (4 of 11) of patients. For the third independent cohort, we re-examined the timing of AI exposure on the previously published index series of ESR1 mutant cancers, none of which had previous exposure to AI in the adjuvant setting alone (Fig. 4C) (9) .
ESR1 mutations can be selected to become the dominant clone in the cancer We assessed the relative clonality of ESR1 mutations in ctDNA, comparing the abundance of ESR1 mutation to other common driver mutations identified with PIK3CA digital PCR and ctDNA MPS. In a patient with sequential samples taken during metastatic treatment, an ESR1 mutation was shown to be selected by previous AI treatment for metastatic cancer to become the dominant clone (Fig. 5A) . We assessed the relative clonal dominance of ESR1 mutation, comparing the allele frequency of the ESR1 mutation with allele frequency of PIK3CA on the same plasma sample. We assumed that most of the PIK3CA mutations are clonal in ER-positive breast cancers and therefore that the relative allele frequency would give an assessment of clonal dominance (within wide limits to take account of potential copy number variation in the tumor). We included an additional patient with a PTEN mutation identified by MPS. This analysis suggested that the ESR1 mutation may be clonally dominant in the tumors of four patients, whereas the ESR1 mutation was likely subclonal in the tumors of two patients (Fig. 5B) . These data suggest that assessment of ESR1 mutation clonality is likely to be important in the development of therapeutics targeting the mutant ER. Finally, we investigated for evidence of loss of ESR1 mutation with time after AI exposure (15) . The rate of detection of ESR1 mutation was unaltered between patients with samples taken at the time of completing AI therapy for metastatic cancer or >6 months later [samples <6 months from completing AI therapy 22% (11 of 50) versus >6 months 41% (7 of 17) ESR1 mutant; P = 0.12, c 2 test], suggesting that once selected by previous AI therapy, the ESR1 mutation may persist in the tumor through subsequent therapy.
DISCUSSION
ctDNA analysis has the potential to allow noninvasive analysis of tumor genetic alterations in advanced cancer. Here, we demonstrate that ctDNA analysis has analytical and clinical validity in the identification of hotspot LBD ESR1 mutations in the plasma of advanced breast cancer patients and has possible clinical utility in identifying a group of patients who derive very limited benefit from further AI therapy.
Our data provide evidence that the mechanism of resistance to targeted therapy, specifically AIs, may differ substantially depending on the setting of exposure. ESR1 mutations are selected frequently during treatment for metastatic breast cancer, likely through selection of rare ESR1 mutant subclones that were present in low amounts before therapy as a result of genetic intratumoral heterogeneity and clonal diversity in the cancer ( fig. S3 ). However, our data suggest that in patients treated in the adjuvant setting with micrometastatic disease, ESR1 mutations are selected/ acquired less frequently, potentially due to a lack of genetic diversity in micrometastatic disease. We speculate that the tumor bulk of micrometastatic disease may be sufficiently low that rare ESR1 mutant subclones are not present and cannot therefore be selected by therapy ( fig. S3 ). We were unable to provide direct evidence that ESR1 mutations preexist before therapy in the metastatic setting. However, we do show that ESR1 mutations are frequently monoclonal, are therefore likely derived from a single cell, arise over a median of 23 months' exposure, and frequently become the dominant clone in the cancer. Given the doubling rate of ERpositive breast cancer (16) , it is relatively unlikely that a single cell could repopulate the metastatic cancer in this time, and therefore, our data suggest that ESR1 mutations likely preexist in the tumor before exposure. However, it is also possible that in cancers with a longer duration of previous AI exposure, the mutation could be acquired during therapy, initiated through mutagenic processes such as the APOBEC enzymes (17) .
Our data illustrate the potential value of ctDNA analysis and the ability to access large unbiased cohorts of patients with pretreated advanced cancer without the potential selection biases inherent in tissue biopsy cohorts, where patients are selected on the basis of suitability for biopsy. Nevertheless, our study has a number of limitations. The studied population is heterogeneously treated, and the sample size does not allow us to examine whether ESR1 mutation detection predicts sensitivity to specific hormone therapies or combinations, for example, fulvestrant or everolimus plus exemestane, respectively. We could not assess the lead time between emergence of ESR1 mutations in ctDNA and clinical progression of the disease because of limited longitudinal sampling. Here, we did not examine less frequent ESR1 mutations (for example, E380Q or S463P), partly because their function has not been studied extensively yet. In line with previous publications, we found D538G to be the most common mutation identified in plasma DNA, although we had insufficient data to address whether there were clinical differences between different ESR1 mutations in the LBD. Finally, in lung cancer, T790M EGFR mutations selected by previous EGFR targeted therapy can be lost during subsequent treatment, possibly because the T790M clone may proliferate more slowly and be "overtaken" by residual wild-type EGFR clones once the selective pressure of EGFR targeted therapy is removed. A similar result has been reported for selected KRAS mutations in colorectal cancer treated with EGFR inhibitors (15) . This could provide an explanation for the low rates of ESR1 mutations in the adjuvant AI setting, if there was intervening non-AI treatment before sampling. We provide two controls to suggest that this is not the main explanation: the subset of patients with a ctDNA sample taken at the time of relapse on AI had very low ESR1 mutation detection, and we observed no mutations in the independent series of tumor biopsies taken at relapse on AI therapy. In addition, our data suggest that ESR1 mutations remain readily detectable in ctDNA many months and years after stopping AI therapy, suggesting possible differences between selected ESR1 mutations in breast cancer and KRAS in colorectal cancer.
Our data provide evidence for the clinical validity of ctDNA ESR1 mutation testing and support ctDNA screening to select patients for prospective clinical trials with drugs that target ESR1 mutations, such as oral ER degraders, which are in early clinical development. ESR1 mutations are rarely acquired during adjuvant AI therapy but are commonly selected by therapy for metastatic disease, providing evidence that the mechanisms of resistance to targeted therapy may be substantially different between the treatment of micrometastatic and overt metastatic cancer.
MATERIALS AND METHODS

Study design
We collected a series of plasma DNA samples from patients with advanced breast cancer to assess the potential utility of ESR1 mutation analysis in ctDNA. We developed multiplex digital PCR assays for hotspot LBD mutations and used these assays to screen for ESR1 mutations. In parallel, a subset of patients had biopsy samples obtained contemporaneously with plasma samples to assess agreement with tumor biopsy, and repeat plasma sampling to assess reproducibility and the ability to mail samples in preservative tubes. We investigated the relationship between detection of ESR1 mutation and sensitivity to subsequent hormonal therapy. We also identified the clinical and pathological features that associated with the presence of an ESR1 mutation and validated these associations in an independent series of 49 tumor biopsies taken on progression on AI therapy.
Patients
We analyzed 171 consecutive patients with advanced breast cancer at the Royal Marsden Hospital (RMH), who consented to tissue collection studies approved by multicenter research ethics committees (ref.
nos. 10/H0805/50 and 11/LO1595). All patients had recently relapsed or progressed after previous therapy.
ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) were assessed in a single laboratory at the Royal Marsden Histopathology department (or reviewed by the RMH when reported from a referring hospital) using standard criteria.
For patients who had biopsy of recurrent cancer, this biopsy was used to define the receptor status, and for the remaining patients, the pathology of the primary cancer was used. For patients who had biopsies from multiple metachronous metastatic sites, the most recent biopsy was used to define the receptor status. Patients who presented with primary breast cancer simultaneously with metastatic disease were recorded as having biopsy of recurrent cancer. Table 1 illustrates the main clinicopathological characteristics of ER-positive patients in this cohort, and table S1 shows the whole cohort.
Patients with previous AI exposure were divided by time of first exposure to AI in the adjuvant setting (treatment with either preoperative AI or adjuvant AI after surgery for early breast cancer or isolated local recurrence and before metastatic relapse) or the metastatic setting (first treatment with an AI after metastatic relapse). Patients were considered to have had plasma samples taken "at time of relapse on AI therapy" when blood was taken within 6 months of stopping adjuvant AI. To analyze associations with subsequent AI-based therapy, PFS was defined as the time from starting AI to documented disease progression or death. Patients receiving AI and an anti-HER2 agent concomitantly were excluded from this analysis. For patients who received chemotherapy after the blood test and then went onto maintenance AI therapy, the baseline date for PFS analysis was the starting date of AI.
An independent validation cohort consisted of a separate series of 49 patients with recurrent breast cancer who were all pretreated with an AI before the recurrent disease biopsy (18) . For 43 of 49 of these cases, a biopsy sample obtained before AI therapy was also available for assessment. First exposure to AI was in the adjuvant setting for 32 of these patients and in the metastatic setting for 17 patients using the above definitions. A further, entirely independent, set of plasma samples was also collected from an additional 28 patients with metastatic breast cancer for additional independent validation.
Processing and DNA extraction from tumor tissue Thirty-one patients in our cohort had tumor biopsies contemporaneous with the plasma samples. Archival formalin-fixed and paraffinembedded (FFPE) tissue blocks were retrieved, and sections (4 to 8 × 4 mm) were cut from these blocks, stained with Nuclear Fast Red, and microdissected to achieve >70% tumor cell purity using a hematoxylin and eosin-stained slide to guide manual microdissection. Tumor DNA was isolated using the QIAamp DNA FFPE Tissue Kit (Qiagen) as per the manufacturer's instructions. DNA was eluted in 50 to 100 ml of ATE buffer, depending on the amount of tumor on the slides, and stored at −20°C until quantification. For the validation cohort, tumor DNA was isolated using the Qiagen AllPrep DNA/RNA FFPE Kit as per the manufacturer's instructions.
Processing of plasma and extraction of circulating DNA Blood collected in Vacutainer EDTA Blood Collection Tubes (BCT) was processed within 2 hours of sample collection and centrifuged at 1600g for 20 min to separate the plasma from the peripheral blood cells. Plasma was stored at −80°C until DNA extraction. DNA was extracted from 2 ml of aliquots of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. The DNA was eluted into 50 ml of buffer AVE and stored at −20°C until quantification. For a subset of patients, to test concordance and alternative methods of blood processing, blood was also placed in Streck Cell-Free DNA BCT tubes at the same visit as the EDTA sample, and shipped at room temperature, with plasma separated 48 to 72 hours after venesection.
DNA quantifications from tissue and/or plasma DNA isolated from tissue or plasma was quantified on a Bio-Rad QX200 Droplet Digital PCR (ddPCR) System using ribonuclease (RNase) P as the reference gene. One microliter of eluate was added to a ddPCR containing 10 ml of ddPCR Supermix for probes (Bio-Rad) and 1 ml of TaqMan Copy Number Reference Assay, human, RNase P (Life Technologies) in a total volume of 20 ml. The reaction was partitioned intõ 14,000 droplets per sample in a QX200 droplet generator according to the manufacturer's instructions. Emulsified PCRs were run on a 96-well plate on a G-Storm GS4 thermal cycler, incubating the plates at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 60 s, then 10-min incubation at 98°C. The temperature ramp increment was 2.5°C/s for all steps. Plates were read on a Bio-Rad QX200 droplet reader with QuantaSoft v1.6.6.0320 software from Bio-Rad. At least two negative control wells with no DNA were included in every run. The amount of amplifiable RNase P DNA was calculated from the concentration provided by the software.
Development of LBD ESR1 mutation digital PCR assays
We designed primer probe combinations for each of the most common ESR1 mutations (p.L536R, p.Y537S, p.Y537N, p.Y537C, and p.D538G) (table S2) using Primer3Plus or Life Technologies' custom SNP genotyping assay tool. Primers and probes were analyzed for the presence of hairpins, secondary structures, or heterodimer/homodimer formation. Primers were analyzed for specificity of the primer pair to their amplicon using University of California, Santa Cruz, ePCR tool (http://genome. ucsc.edu/cgi-bin/hgPcr?command=start). Digital PCR conditions were optimized with a temperature gradient to identify the optimal annealing/ extension temperature using wild-type DNA spiked with a mutant synthetic oligonucleotide (table S2) on a QX200 ddPCR system (Bio-Rad) using TaqMan chemistry. We developed multiplex assays varying the concentration of the fluorescent probes to differentiate mutations on the basis of fluorescence intensity (19) . We selected the two optimal multiplex assay combinations (multiplexes 1 and 2) and probe concentrations as shown in table S2.
Limit of detection of ESR1 assays
Genomic DNA (gDNA) was extracted from the ESR1 wild-type human mammary gland cell line CAMA-1 (American Type Culture Collection HTB-21) with DNeasy Blood and Tissue Kit (Qiagen) as per the manufacturer's instructions. DNA was quantified using Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies) as per the manufacturer's instructions. We spiked 15,000 genomes of STR-typed CAMA-1 gDNA with 200, 100, 5, and 3 copies of mutant D538G DNA and ran a uniplex digital PCR with the primers and probes for this mutation (table S2) as described above. We calculated the number of copies assayed versus the frequency of mutation detected after digital PCR cycling and plotted it to assess the lower limit of detection for this assay.
Hotspot PIK3CA mutation digital PCR assays Digital PCR assays for the four most common occurring mutations in the PIK3CA gene-E542K (c.1624G>A), E545K (c.1633G>A), H1047L (c.3140A>T), and H1047R (c.3140A>G)-were developed as for ESR1 LBD assays, using TaqMan probes [FAM (fluorescein)-labeled for mutant and VIC-labeled for wild type], and have been described previously (20) . We developed a multiplex assay varying the concentration of the fluorescent probes to differentiate mutations on the basis of fluorescence intensity as above, and we selected the optimal multiplex assay combination and probe concentrations, which enabled us to test for the four hotspot mutations in one single reaction. PIK3CA mutation testing in ctDNA was performed in a subgroup of the cohort (109 of 128 ER-positive patients) who had sufficient residual plasma for analysis.
Digital PCR analysis of circulating free DNA and tumor tissue DNA Digital PCR was performed on a QX200 digital PCR system (Bio-Rad) using the assays described in table S2. For plasma samples, circulating free DNA (cfDNA) equivalent to 250 ml of plasma was used per multiplex assay. For tumor tissue DNA, 1 ng was used per multiplex assay. PCRs were prepared with digital PCR Supermix for probes (Bio-Rad) and partitioned into a median of~14,000 droplets per well in a QX200 droplet generator according to the manufacturer's instructions. Emulsified PCRs were run on a 96-well plate on a G-Storm GS4 thermal cycler, incubating the plates at 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 60 s, then 10-min incubation at 98°C. The temperature ramp increment was 2.5°C/s for all steps. Plates were read on a Bio-Rad QX200 droplet reader with QuantaSoft v1. 6.6.0320 software from Bio-Rad to assess the number of droplets positive for mutant DNA, wild-type DNA, both, or neither. At least two negative control wells with no DNA were included in every run. A mutation was considered positive with at least two ESR1 mutant (or PIK3CA) droplets. The multiplex digital PCR was performed for mutation detection, and the individual mutation or mutations present were subsequently confirmed with uniplex digital PCR assays.
Digital PCR analysis
The concentration of mutant DNA (copies of mutant DNA per droplet) was estimated from the Poisson distribution. The number of mutant copies per droplet was calculated as Mmu = −ln (1 − (nmu/n)), where nmu is the number of droplets positive for mutant-FAM probe and n is the total number of droplets. The DNA concentration in the reaction was estimated as follows: MDNAconc = −ln (1 − (nDNAconc/n)), where nDNAconc is the number of droplets positive for mutant-FAM probe and wild type-VIC probe and n is the total number of droplets. The mutation allele fraction = Mmu/MDNAconc. The number of mutant copies per milliliter of plasma was estimated from the mutation allele fraction by taking into account the number of wells run for the sample and the volume equivalent of plasma run, and the mean volume of a droplet (0.89 pl) using the following formula:
Mutant copies per ml = (total number of droplets positive for FAM and/or VIC × 20,000)/total number of droplets read/0.89 × (number of droplets/volume of plasma equivalents)
Ion Torrent Proton sequencing of plasma samples Sequencing libraries were prepared with a custom Ion AmpliSeq Breast Cancer Panel targeting 14 known breast cancer driver and focal mutations (table S3) using the Ion AmpliSeq Library Preparation protocol with 3 ng of cfDNA, according to the manufacturer's instructions. After barcoding, libraries were quantified using qPCR, diluted to 100 pM, and pooled. Libraries were templated with the Ion OneTouch2 system (Life Technologies) and sequenced on a PI chip using the Ion PI OT2 200 Kit (Life Technologies), 520 flows, and an average amplicon length of 97 bases to a mean depth of ×9183. The sequencing resulted in 1,042,543 to 5,763,164 reads per sample. Ion Torrent Variant Caller v4.0-r73742 with no hotspot region and configuration "Germ Line Low Stringency" was used for calling variants. Read counts for all positions were computed using pileup [SAMtools v1.1 (21) ], and these data were analyzed for possible variants using custom perl and R scripts. Variants at >3% reported by both analysis methods and not reported in 1000 Genomes Project database (www.1000genomes.org) were identified as possible somatic mutations. The data were cross-referenced against the Cosmic database v70 (cancer.sanger.ac.uk) to identify possible hotspot mutations. Variants not appearing in the 1000 Genomes database were taken forward for validation by digital PCR assays.
Statistical analysis
All statistical analysis was performed with GraphPad Prism version 6.0 or Microsoft Excel. Unless stated otherwise, P values were two-tailed and considered significant if P < 0.05.
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